文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

药物诱导的自组装纳米囊泡通过自噬抑制和递送同步逆转多柔比星耐药性。

Drug-induced self-assembled nanovesicles for doxorubicin resistance reversal via autophagy inhibition and delivery synchronism.

机构信息

Ministry of Educational (MOE) Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China.

出版信息

Theranostics. 2022 May 13;12(8):3977-3994. doi: 10.7150/thno.70852. eCollection 2022.

DOI:10.7150/thno.70852
PMID:35664062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9131275/
Abstract

As a classical autophagy inhibitor, CQ has been supposed to increase the sensitivity of tumors to chemotherapeutics. However, there exists a quite huge gap between laboratory research and clinical application, which is related to the distinct pharmacokinetic behavior of CQ to a great extent. Based on amphiphilic copolymer PPAP, a pH-responsive drug-induced self-assembled nanovesicle, named DC-DIV/C, was constructed to load DOX⋅HCl and CQ. The physicochemical properties of DC-DIV/C were characterized. To validate the cooperative action and delivery synchronism of DOX⋅HCl and CQ, cytotoxicity, apoptosis, cellular uptake and autophagy assay were investigated in DOX⋅HCl resistant cancer cells. The pharmacokinetic character and antitumor effect of DC-DIV/C were evaluated on rats and nude mice bearing xenograft drug-resistant K562/ADR tumors, respectively. DC-DIV/C could simultaneously encapsulate DOX·HCl and CQ at the optimal ratio of 1:2. In vitro and in vivo tests confirmed that DC-DIV/C acted as an excellent vehicle for the synchronous delivery of DOX⋅HCl and CQ during the process of blood circulation, cellular uptake and intracellular release. Furthermore, CQ accomplished autophagy inhibition to reduce the IC of DOX⋅HCl resistant cancer cells. Consequently, DC-DIV/C exhibited the extremely improved anti-tumor effect with 84.52% TIR on K562/ADR tumor. This study provides a promising and powerful strategy to achieve enhanced treatment outcomes for the precise combination therapy.

摘要

作为一种经典的自噬抑制剂，CQ 被认为可以提高肿瘤对化疗药物的敏感性。然而，实验室研究与临床应用之间存在着相当大的差距，这在很大程度上与 CQ 截然不同的药代动力学行为有关。基于两亲性嵌段共聚物 PPAP，构建了一种 pH 响应的药物诱导自组装纳米囊泡，命名为 DC-DIV/C，用于装载 DOX·HCl 和 CQ。对 DC-DIV/C 的理化性质进行了表征。为了验证 DOX·HCl 和 CQ 的协同作用和递药同步性，在 DOX·HCl 耐药癌细胞中进行了细胞毒性、凋亡、细胞摄取和自噬实验。分别在荷瘤耐药 K562/ADR 肿瘤大鼠和裸鼠中评价了 DC-DIV/C 的药代动力学特征和抗肿瘤作用。DC-DIV/C 可以在最佳比例 1:2 同时包载 DOX·HCl 和 CQ。体外和体内实验证实，DC-DIV/C 在血液循环、细胞摄取和细胞内释放过程中是一种同时递运 DOX·HCl 和 CQ 的优秀载体。此外，CQ 完成自噬抑制以降低 DOX·HCl 耐药癌细胞的 IC。因此，DC-DIV/C 对 K562/ADR 肿瘤表现出了极好的抗肿瘤效果，TIR 为 84.52%。本研究为精确联合治疗提供了一种有前途的、强大的策略，以实现治疗效果的增强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/0ee43c98be62/thnov12p3977g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/9be4d51f8284/thnov12p3977g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/2bc162156453/thnov12p3977g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/6246ab94908f/thnov12p3977g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/4f87d7b7bb3a/thnov12p3977g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/5bb4d05d3f10/thnov12p3977g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/aca1e448c3f0/thnov12p3977g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/d0b6076f75f6/thnov12p3977g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/0ee43c98be62/thnov12p3977g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/9be4d51f8284/thnov12p3977g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/2bc162156453/thnov12p3977g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/6246ab94908f/thnov12p3977g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/4f87d7b7bb3a/thnov12p3977g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/5bb4d05d3f10/thnov12p3977g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/aca1e448c3f0/thnov12p3977g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/d0b6076f75f6/thnov12p3977g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b95/9131275/0ee43c98be62/thnov12p3977g008.jpg

相似文献

[1]
Drug-induced self-assembled nanovesicles for doxorubicin resistance reversal via autophagy inhibition and delivery synchronism.

Theranostics. 2022

[2]
Polyphosphazene vesicles for co-delivery of doxorubicin and chloroquine with enhanced anticancer efficacy by drug resistance reversal.

Int J Pharm. 2016-2-10

[3]
Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.

J Liposome Res. 2017-6

[4]
Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro.

Nanotechnology. 2018-11-30

[5]
Mitochondria-targeted vitamin E succinate delivery for reversal of multidrug resistance.

J Control Release. 2021-9-10

[6]
Chloroquine reverses chemoresistance via upregulation of p21 and autophagy inhibition in ovarian cancer.

Cell Death Dis. 2020-12-4

[7]
The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.

J Thorac Oncol. 2013-6

[8]
Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.

Neurosurg Focus. 2014-12

[9]
Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance.

Int J Pharm. 2015-11-30

[10]
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.

J Transl Med. 2022-6-27

引用本文的文献

[1]
Polyphosphazene-Based Nanotherapeutics.

J Funct Biomater. 2025-8-2

[2]
Dual-Drug Delivery Systems Using Hydrogel-Nanoparticle Composites: Recent Advances and Key Applications.

Gels. 2025-7-3

[3]
Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.

Small Sci. 2025-4-11

[4]
Lysosomal gene ATP6AP1 promotes doxorubicin resistance via up-regulating autophagic flux in breast cancer.

Cancer Cell Int. 2024-12-3

[5]
A comprehensive landscape analysis of autophagy in cancer development and drug resistance.

Front Immunol. 2024

[6]
Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies.

ACS Omega. 2024-6-18

[7]
Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment.

Int J Mol Sci. 2024-1-12

本文引用的文献

[1]
Furin-instructed aggregated gold nanoparticles for re-educating tumor associated macrophages and overcoming breast cancer chemoresistance.

Biomaterials. 2021-8

[2]
Drug -driven self-assembly of pH-sensitive nano-vesicles with high loading capacity and anti-tumor efficacy.

Biomater Sci. 2021-5-4

[3]
Autophagy in tumour immunity and therapy.

Nat Rev Cancer. 2021-5

[4]
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial.

Autophagy. 2021-9

[5]
Development of a pH-responsive polymersome inducing endoplasmic reticulum stress and autophagy blockade.

Sci Adv. 2020-7-31

[6]
Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment.

Nano Lett. 2019-10-17

[7]
Enhancing tumor chemotherapy and overcoming drug resistance through autophagy-mediated intracellular dissolution of zinc oxide nanoparticles.

Nanoscale. 2019-6-20

[8]
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Nat Med. 2019-3-4

[9]
Effective intracellular delivery and Th1 immune response induced by ovalbumin loaded in pH-responsive polyphosphazene polymersomes.

Nanomedicine. 2018-4-9

[10]
Autophagy and multidrug resistance in cancer.

Chin J Cancer. 2017-6-24

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索